

11th Cambridge Upper GI Symposium: Masterclass in Upper GI Neoplasia



17th March 2023

Venue: CRUK Cambridge Institute, Robinson Way, CB2 0RE

Sign up link: <https://onlinesales.admin.cam.ac.uk/conferences-and-events/mrc-cancer-unit/cambridge-upper-gi-symposium/cambridge-upper-gi-symposium>

Registration fee:
£50: Consultants
£25: Non-consultants
£10: Addenbrookes staff

CPD points provided
Hot meals provided

Masterclass in Upper GI Neoplasia 17th March 2023

09:00 – 09:15	Welcome - Massimiliano di Pietro
Pre-malignant Diseases (Chair: Dr Massimiliano di Pietro)	
09:15 – 09:40	Origin of Barrett's Oesophagus John Zhuang, University of Cambridge
09:40 – 10:05	Gastric Intestinal Metaplasia Risk Stratification Manon Spaander, Erasmus Medical Centre, Rotterdam, Netherlands
10:00 – 10:25	Histopathological Perspective for Gastric Intestinal Metaplasia Marnix Jansen, University College London
10:30 – 10:55	Video Case: Surveillance of Barrett's oesophagus and Gastric Intestinal Metaplasia W. Keith Tan, University of Cambridge
10:55 – 11:30	Coffee Break
Early Cancer (Chair: Dr Ines Modolell)	
11:30 – 11:55	Role of p53 in Barrett's Oesophagus Pathology Phillip Kaye, University of Nottingham
11:55 – 12:20	Post-endoscopy Upper GI Cancer Leo Alexandre, University of East Anglia
12:20 – 12:45	New NICE Guidelines on the Management of Barrett's Oesophagus and Related Neoplasia Massimiliano di Pietro, University of Cambridge
12:45 – 13:10	Video Case & Panel Discussion: treatment of early neoplastic lesions of the upper GI tract Judith Honing, Erasmus; Manon Spaander, Erasmus; Rob O'Neil, Cambridge, Massimiliano di Pietro, Cambridge
13:10 – 14:00	Lunch Break
Malignant Disease & MDT Discussion (Chair: Prof Rebecca Fitzgerald) (3-5 min case discussion, 17-18 min presentation and 8-10 min MDT discussion)	
14:00 – 14:30	Gastro-intestinal Stromal Tumour Ramesh Bulusu, University of Cambridge
14:30 – 15:00	Targeted Therapy for Upper GI Cancer Elizabeth Smyth, University of Cambridge
15:00 – 15:30	Is There Still a Role for Radiotherapy in Oesophageal Adenocarcinoma Ganesh Radhakrishna, The Christie NHS Foundation Trust
15:30 – 16:00	Clinical Fitness for Upper GI Cancer Surgery Rob O'Neil, University of Cambridge
16:00 – 16:10	Closing - Massimiliano di Pietro





Dr John Lizhe Zhuang

Dr John Zhuang is a senior post-Doc in the Fitzgerald laboratory whose research focuses on oesophageal adenocarcinoma and its precancerous lesion Barrett's oesophagus, and it is built around two key interactive directions:

- 1) establishment of patient and disease-free organ donor derived in vitro organoid and co-culture models, to modulate the initiation and development of Barrett's oesophagus and its progression towards oesophageal adenocarcinoma, and investigate the heterogenous and dynamic genomic landscapes in the context of microenvironment (niche factors, disease related refluxate and local inflammation), as well as drug treatment (targeted or immune therapies)
- 2) using state-of-the-art multiplex imaging technology and machine-learning computational approaches to profile a detailed 'atlas' of immune and stromal cells directly on patient tissue sections, and characterize their cell density, composition and spatial correlation in the disease progression and/or under treatment.

Prof. Manon Spaader

Prof. Manon Spaander is a professor in early detection and screening of premalignant gastrointestinal disease at the Erasmus Medical Center in Rotterdam. She is involved in the national bowel screening program in the Netherlands and her research group focusses on early detection of both lower and upper GI premalignant conditions. She has also participated in several guideline publications including the recent ESGE benign and malignant oesophageal stent guideline.

Dr Marnix Jansen

Dr Marnix Jansen is a Cancer Research UK (CRUK) Clinician Scientist and Honorary Consultant Histopathologist at University College Hospitals London NHS Trust and UCL Cancer Institute. Dr Jansen trained in the Academic Medical Center (AMC) in Amsterdam. He obtained his PhD in the laboratory of Hans Clevers at the Hubrecht Institute for Stem Cell Research. After obtaining a Translational Cancer Research Fellowship awarded by the Dutch Cancer Society (KWF), he moved to the laboratory of Sir Nicholas Wright at Barts Cancer Institute in London. He has also undertaken combined clinical and research training at the pathology departments of the Johns Hopkins Medical Institutes in Baltimore, USA and the National Cancer Centre Hospital in Tokyo, Japan. The work in his research group at UCL Cancer Institute focuses on stem cell evolution in Barrett's dysplasia and the preneoplastic stomach, and on computer vision approaches in digital pathology.

Dr W. Keith Tan

Dr W. Keith Tan is a gastroenterology registrar and a Cancer Research UK (CRUK) Clinical PhD Fellowship award holder and currently pursuing his PhD with Professor Rebecca Fitzgerald and Dr Massimiliano di Pietro at the Early Cancer Institute, Cambridge. He previously held positions as an Academic Foundation Trainee (Academic Medicine) followed by an NIHR Academic Clinical Fellowship in Gastroenterology & Hepatology, both at the University of Cambridge. Over the years, he has spent time abroad in world renowned institutions including sub-internships at the Cleveland Clinic, Ohio, Mayo Clinic, Rochester and an academic placement at the University of North Carolina, Chapel Hill. His research interest is in the use of non-endoscopic devices in screening and surveillance of Barrett's oesophagus. He has authored several peer-reviewed publications, book chapters, and review articles in the field of Barrett's oesophagus, including being lead-author of a book entitled 'How to Succeed in the Academic Clinical Interview' (Cambridge University Press). More recently, he has been part of the ESGE guidelines committee for the revised Barrett's oesophagus guidelines. He also wrote the BEST4 platform study grant, a £6 million project for which he is a junior investigator.

Speakers Profile

Prof. Rebecca Fitzgerald

Prof. Rebecca Fitzgerald is Professor of Cancer Prevention at the Early Cancer Institute in Cambridge. Prof. Fitzgerald is known from the development of the Cytosponge-TFF3 test for Barrett's oesophagus detection. She is Programme Leader (tenure) and an Honorary Consultant in Gastroenterology and General Medicine at Addenbrooke's Hospital, Cambridge. She also holds a personal chair in Cancer Prevention at the University of Cambridge and chairs the Upper GI MDT.

Dr Philip Kaye

Dr Phillip Kaye graduated from the University of Cape Town medical School in 1988 and subsequently pursued an honours degree in medical biochemistry and before specialising in histopathology. After spending a few years as a consultant in Cape Town, he moved to UK and a couple of years later took up my current position as a consultant in histopathology specialising in GI pathology in Nottingham in 2002. Here, he developed research interests in Barrett oesophagus and other aspects of upper GI pathology as well as areas of liver pathology. He became particularly interested in the role of p53 in Barrett's neoplasia progression and particularly in its use as a tool for improving reliability of pathology diagnosis of dysplasia and prediction of progression, and in this work, he collaborated with colleagues regionally and nationally and abroad. He has contributed to the pathological aspect of Barrett's oesophagus and other guidelines for the BSG and NICE. In his spare time, he enjoys walking, running and birding.

Dr Leo Alexandre

Dr. Leo Alexandre is clinical associate professor at Norwich Medical School, University of East Anglia, and honorary consultant gastroenterologist at the Norfolk and Norwich University Hospital. He has an interest in the epidemiology of pre-malignant and malignant upper gastrointestinal disease. A key theme of his research is the application of epidemiological methods using routinely collected health data to develop interventions to improve outcomes in patients with upper gastrointestinal malignancy.

Dr Massimiliano di Pietro

Dr Massimiliano di Pietro is a Senior Clinician Scientist at the Early Cancer Institute and Honorary Consultant Gastroenterologist in Addenbrookes Hospital, Cambridge. He qualified from Federico II University of Naples, Italy. From 2001 to 2003 he did an MD research project at the Institute of Molecular Cancer Research (University of Zurich, Switzerland) studying transcriptional signatures in colon cancers with microsatellite instability. He completed his specialist training in Gastroenterology in 2007 at the University Hospital of Naples, Italy. Shortly after he joined the Academic Department of Gastroenterology at Cambridge University Hospitals as Clinical Lecturer and developed a research interest in Barrett's oesophagus. As research fellow in Prof. Fitzgerald's laboratory, he developed research projects investigating different aspects of Barrett's oesophagus, including molecular pathogenesis, tissue biomarkers and endoscopic imaging tools. Since 2010 he has been Honorary Consultant Gastroenterologist in Addenbrooke's hospital. Dr di Pietro currently provides regional referral for endoscopic therapy for gastric early cancer, dysplastic Barrett's oesophagus and early oesophageal cancer, including EMR, ESD and RFA and national referral for endoscopic surveillance of hereditary diffuse gastric cancer. His research focuses on Barrett's oesophagus and early gastric cancer with particular interest in biomarkers for risk stratification, imaging tools for dysplasia detection and diagnostic quality indicators. Dr di Pietro has authored several peer-reviewed publications, book chapters and review articles in the field upper GI premalignant and early malignant conditions. He was topic adviser for the 2023 Barrett's oesophagus NICE guidelines and currently working as task force leader for the ESGE Barrett's oesophagus guidelines. In his spare time, he enjoys playing tennis and coaching football.

Dr Judith Honing

Judith Honing is a newly appointed consultant gastroenterologist at the Erasmus Medical Center in Rotterdam. In 2014 she finished her PhD in the department of Surgery and Medical Oncology at the University Medical Center Groningen, regarding cancer stem cells in esophageal cancer and novel biomarkers. After her PhD, she started her Gastroenterology training at the University Medical Center Utrecht. In 2021 she started as a Clinical Research Associate at the University of Cambridge, where she worked closely with Prof Rebecca Fitzgerald and Dr Massimiliano di Pietro. She has an interest in the detection and treatment of premalignant upper GI conditions including Barrett's oesophagus and (hereditary) gastric premalignant conditions. Her research is aimed at improving screening and surveillance for these diseases and identifying novel biomarkers which predict progression.





Dr Ramesh Bulusu

Dr Ramesh Bulusu is a consultant Oncologist at Addenbrookes Hospital, Cambridge. He trained at the Beatson Oncology Centre, Glasgow, Addenbrooke's Hospital, Cambridge and Churchill hospital, Oxford, before taking up his consultant position in Addenbrooke's hospital in Cambridge in 2002. Dr Bulusu is the founder/chairman of the Cambridge Gastrointestinal Stromal Tumour (GIST) Study Group and the network lead for GISTs in Cambridge. He has served as the Track leader and member of the Sarcoma Track of the American Society of Clinical Oncology Scientific Committee from 2013-2017. His primary interest is working towards the better understanding of the biology of paediatric wild type GISTs. He has established a national charity for paediatric wild type GIST and he is the UK lead for the PAWS-GIST (paediatric, adolescent, wild type, syndromic Gastrointestinal stromal tumour) consortium. In Cambridge, his team offers a national service and run National clinic here in Cambridge. The PAWS GIST consortium is focussing on the clinical, biological and molecular basis for treatment of these rare subtypes of GIST. He collaborates with the NIH team at Bethesda for new drug development and work closely with other GIST researchers in Europe and USA.

Dr Elizabeth Smyth

Dr Elizabeth (Lizzy) Smyth is consultant in gastrointestinal oncology at Addenbrooke's Hospital, Cambridge. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded an Irish Society of Medical Oncology fellowship to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society of Medical Oncology Faculty GI educational faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Ganesh Radhakrishna

Dr Ganesh Radhakrishna is a Clinical Oncologist at The Christie NHS Foundation trust and has a specialist interest in treating upper and lower gastrointestinal cancers. He provides oncological treatments in ranging from systemic chemotherapy to highly sophisticated precision external beam radiation therapy and brachytherapy. He works closely with other specialties including radiology, surgery, medical oncology and palliative care. He delivers a whole spectrum of anti-cancer treatment from palliative treatment for disease and symptoms control, to curative treatments. He is very involved in the delivery and development of clinical trials and has a keen interest in clinical education and since clinical oncology is a small craft specialty, he has been able to further this interest further by studying the impact of varying teaching methods to improve training for the specialty at a regional and national level. He enjoys his roles as a clinical oncologist which seamlessly combines the technical and scientific aspects of medicine by integrating basic science (e.g. cancer biology) and therapeutics (e.g. applying advanced precision radiation and drug therapeutics) with the art of medicine, which involves delivering holistic individualised patient centred care throughout their cancer journey.

Mr Rob O'Neill

Mr. O'Neill is a consultant upper GI surgeon at Addenbrookes Hospital, Cambridge. He graduated from Edinburgh Medical School with Honours in 2005 and joined the South-East Scotland surgical training programme in 2007. He was appointed to the ECAT training programme in 2009 and completed his PhD in the Edinburgh Cancer Research Centre in 2013 under the supervision of Professor Ted Hupp and Professor Rebecca Fitzgerald. His research aims to identify novel therapeutic targets for this disease. He has established an oesophageal tissue resource and is using proteomic methods to identify cancer-specific proteins and computational and network analysis methods to understand OAC biology. He leads the Edinburgh component of the OCCAMS multicentre collaborative; currently undertaking the oesophageal adenocarcinoma genome project. He has both wet-lab, computational and clinical research studies in progress and welcome motivated students to get in touch by email if they are interested in joining this work.

BIOHIT HealthCare

Innovating for Health

The logo for SYNMED features the word "SYNMED" in a bold, sans-serif font. The letters "S", "Y", and "M" are in blue, while "N", "E", and "D" are in grey. The text is enclosed within a blue, horizontal oval shape that has a slight 3D effect.The logo for Dr Falk consists of the words "Dr Falk" written in a blue, cursive script font. This text is contained within a blue oval, which is itself centered within a blue square border.

Sponsors



Medtronic

Aquillant
A HC2I Group Company

 **3-D MATRIX**
MEDICAL TECHNOLOGY



Cyted



11th Cambridge Upper GI Symposium

17th March 2023
Cambridge